FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2602353650> ?p ?o ?g. }

• W2602353650 endingPage "266" @default.
• W2602353650 startingPage "250" @default.
• W2602353650 abstract "It remains unclear whether patients with a suspicion of prostate cancer (PCa) and negative multiparametric magnetic resonance imaging (mpMRI) can safely obviate prostate biopsy. To systematically review the literature assessing the negative predictive value (NPV) of mpMRI in patients with a suspicion of PCa. The Embase, Medline, and Cochrane databases were searched up to February 2016. Studies reporting prebiopsy mpMRI results using transrectal or transperineal biopsy as a reference standard were included. We further selected for meta-analysis studies with at least 10-core biopsies as the reference standard, mpMRI comprising at least T2-weighted and diffusion-weighted imaging, positive mpMRI defined as a Prostate Imaging Reporting Data System/Likert score of ≥3/5 or ≥4/5, and results reported at patient level for the detection of overall PCa or clinically significant PCa (csPCa) defined as Gleason ≥7 cancer. A total of 48 studies (9613 patients) were eligible for inclusion. At patient level, the median prevalence was 50.4% (interquartile range [IQR], 36.4–57.7%) for overall cancer and 32.9% (IQR, 28.1–37.2%) for csPCa. The median mpMRI NPV was 82.4% (IQR, 69.0–92.4%) for overall cancer and 88.1% (IQR, 85.7–92.3) for csPCa. NPV significantly decreased when cancer prevalence increased, for overall cancer (r = –0.64, p < 0.0001) and csPCa (r = –0.75, p = 0.032). Eight studies fulfilled the inclusion criteria for meta-analysis. Seven reported results for overall PCa. When the overall PCa prevalence increased from 30% to 60%, the combined NPV estimates decreased from 88% (95% confidence interval [95% CI], 77–99%) to 67% (95% CI, 56–79%) for a cut-off score of 3/5. Only one study selected for meta-analysis reported results for Gleason ≥7 cancers, with a positive biopsy rate of 29.3%. The corresponding NPV for a cut-off score of ≥3/5 was 87.9%. The NPV of mpMRI varied greatly depending on study design, cancer prevalence, and definitions of positive mpMRI and csPCa. As cancer prevalence was highly variable among series, risk stratification of patients should be the initial step before considering prebiopsy mpMRI and defining those in whom biopsy may be omitted when the mpMRI is negative. This systematic review examined if multiparametric magnetic resonance imaging (MRI) scan can be used to reliably predict the absence of prostate cancer in patients suspected of having prostate cancer, thereby avoiding a prostate biopsy. The results suggest that whilst it is a promising tool, it is not accurate enough to replace prostate biopsy in such patients, mainly because its accuracy is variable and influenced by the prostate cancer risk. However, its performance can be enhanced if there were more accurate ways of determining the risk of having prostate cancer. When such tools are available, it should be possible to use an MRI scan to avoid biopsy in patients at a low risk of prostate cancer." @default.
• W2602353650 created "2017-04-07" @default.
• W2602353650 creator A5002985141 @default.
• W2602353650 creator A5004351505 @default.
• W2602353650 creator A5004584899 @default.
• W2602353650 creator A5011133286 @default.
• W2602353650 creator A5013864806 @default.
• W2602353650 creator A5016345321 @default.
• W2602353650 creator A5018595176 @default.
• W2602353650 creator A5019052630 @default.
• W2602353650 creator A5019998379 @default.
• W2602353650 creator A5023131151 @default.
• W2602353650 creator A5046215402 @default.
• W2602353650 creator A5053854071 @default.
• W2602353650 creator A5056479059 @default.
• W2602353650 creator A5057500759 @default.
• W2602353650 creator A5063466486 @default.
• W2602353650 creator A5068797509 @default.
• W2602353650 creator A5071909609 @default.
• W2602353650 creator A5073525360 @default.
• W2602353650 creator A5074756323 @default.
• W2602353650 creator A5075511405 @default.
• W2602353650 creator A5075546358 @default.
• W2602353650 creator A5078216208 @default.
• W2602353650 creator A5084120344 @default.
• W2602353650 creator A5089586523 @default.
• W2602353650 date "2017-08-01" @default.
• W2602353650 modified "2023-10-14" @default.
• W2602353650 title "What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel" @default.
• W2602353650 cites W111429850 @default.
• W2602353650 cites W1494521255 @default.
• W2602353650 cites W1514451204 @default.
• W2602353650 cites W1543674345 @default.
• W2602353650 cites W1589956260 @default.
• W2602353650 cites W1782785910 @default.
• W2602353650 cites W1827911007 @default.
• W2602353650 cites W1882630286 @default.
• W2602353650 cites W1892627793 @default.
• W2602353650 cites W1918088834 @default.
• W2602353650 cites W1966992665 @default.
• W2602353650 cites W1971237277 @default.
• W2602353650 cites W1971825464 @default.
• W2602353650 cites W1977954273 @default.
• W2602353650 cites W1980933880 @default.
• W2602353650 cites W1987395492 @default.
• W2602353650 cites W1987853395 @default.
• W2602353650 cites W1990846633 @default.
• W2602353650 cites W1996166975 @default.
• W2602353650 cites W2001291545 @default.
• W2602353650 cites W2003854483 @default.
• W2602353650 cites W2005501262 @default.
• W2602353650 cites W2007144217 @default.
• W2602353650 cites W2012650059 @default.
• W2602353650 cites W2015165432 @default.
• W2602353650 cites W2016809511 @default.
• W2602353650 cites W2019597341 @default.
• W2602353650 cites W2022711804 @default.
• W2602353650 cites W2023834242 @default.
• W2602353650 cites W2025633811 @default.
• W2602353650 cites W2028700392 @default.
• W2602353650 cites W2031348287 @default.
• W2602353650 cites W2034203827 @default.
• W2602353650 cites W2041705103 @default.
• W2602353650 cites W2042635688 @default.
• W2602353650 cites W2042929851 @default.
• W2602353650 cites W2046268174 @default.
• W2602353650 cites W2050214437 @default.
• W2602353650 cites W2059559115 @default.
• W2602353650 cites W2065170861 @default.
• W2602353650 cites W2069033774 @default.
• W2602353650 cites W2080725537 @default.
• W2602353650 cites W2101373837 @default.
• W2602353650 cites W2107638293 @default.
• W2602353650 cites W2108009703 @default.
• W2602353650 cites W2109474926 @default.
• W2602353650 cites W2112271714 @default.
• W2602353650 cites W2114120552 @default.
• W2602353650 cites W2118712500 @default.
• W2602353650 cites W2119944369 @default.
• W2602353650 cites W2122754822 @default.
• W2602353650 cites W2124539070 @default.
• W2602353650 cites W2128409425 @default.
• W2602353650 cites W2129312832 @default.
• W2602353650 cites W2134628744 @default.
• W2602353650 cites W2134704254 @default.
• W2602353650 cites W2136217059 @default.
• W2602353650 cites W2137380457 @default.
• W2602353650 cites W2137817722 @default.
• W2602353650 cites W2138237120 @default.
• W2602353650 cites W2143884385 @default.
• W2602353650 cites W2152440352 @default.
• W2602353650 cites W2154093292 @default.
• W2602353650 cites W2160223041 @default.
• W2602353650 cites W2164364841 @default.
• W2602353650 cites W2215484848 @default.
• W2602353650 cites W2253262801 @default.
• W2602353650 cites W2284844723 @default.
• W2602353650 cites W2288851487 @default.

• next